Therapeutic Solutions International Licenses Dexosome Clinical Stage Cancer Immunotherapy Product From Gustave Roussy European Cancer Centre
Therapeutic Solutions International, Inc., (OTCPINK:TSOI) signed an exclusive intellectual property license agreement with Gustave for an issued US patent covering the clinically tested “Dexosome” cancer immunotherapy product.
Therapeutic Solutions International, Inc., (OTCPINK:TSOI) signed an exclusive intellectual property license agreement with Gustave Roussy Transfert for an issued US patent covering the clinically tested “Dexosome” cancer immunotherapy product.
According to the company press release:
Dexosomes are exosome nanoparticles generated by dendritic cells, which have previously been used by investigators at Anosys, Inc., in collaboration with researchers at Duke University, for treatment of cancer patients as part of an FDA-cleared Phase I clinical trial(1). The licensed patent was invented by internationally-renowned immunologists Sebastian Amigorena, Doctor at the Curie Institute, and Laurence Zitvogel, Professor at Gustave Roussy. While the patent was issued when licensed to Anoysis, subsequent to merger between Anosys, Inc. and Epimmune, the patent was reverted to Gustave Roussy Transfert. The patent covers means of generating therapeutically-effective dexosomes, which can act as a platform for loading any tumor antigen desired.
Timothy Dixon, President and CEO of TSOI commented:
We are extremely fortunate to obtain this license of a technology in which clinical safety and proof-of-concept already exists. In the area of drug development, much of the risk is taking the technology from the lab to the patient. We are fortunate that the current technology has already been utilized in patients under FDA jurisdiction, and has demonstrated safety with signs of efficacy.